Compound lipophilicity for substrate binding to human P450s in drug metabolism

Drug Discovery Today

Volumn 9, Issue 12, 2004, Pages 530-537

  Lewis, David F V ^a   Jacobs, Miriam N ^a   Dickins, Maurice ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Biochemistry; Cytochromes P450; Drug Discovery; Drug Metabolism; Lipophilicity; Molecular Medicine; Pharmaceutical Science

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 4 NITROPHENOL; 7 ETHOXYCOUMARIN; AMFEBUTAMONE; ARTEETHER; BENZPHETAMINE; CARBAMAZEPINE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2A; CYTOCHROME P450 3A; DIAZEPAM; ENZYME INHIBITOR; IMIPRAMINE; LIDOCAINE; LOSIGAMONE; MEPHENYTOIN; METHYLINDOLE; NAPROXEN; NIFEDIPINE; PHENAZONE; PROGUANIL; PROPOFOL; PROPRANOLOL; ROSIGLITAZONE; SELEGILINE; STATIN; TESTOSTERONE; UNINDEXED DRUG; XENOBIOTIC AGENT;

BINDING AFFINITY; DRUG BINDING; DRUG METABOLISM; ENERGY; ENZYME ACTIVITY; ENZYME SUBSTRATE; HYDROGEN BOND; INFORMATION; LIPOPHILICITY; MOLECULAR MODEL; PROTEIN FAMILY; REVIEW;

BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

EID: 2942625954     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03115-0     Document Type: Review

References (61)

1. Lewis D.F.V. Cytochromes P450: Structure, Function and Mechanism. 1996;Taylor & Francis, London
2. Lewis D.F.V. Guide to Cytochromes P450 Structure and Function. 2001;Taylor & Francis, London
3. Stegeman J.J., Livingstone D.R. Forms and functions of cytochrome P450. Comp. Biochem. Physiol. C. 121:1998;1-3
4. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34:2002;83-448
5. Rendic S., DiCarlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 29:1997;413-580
6. Shimada T., et al. Inter-individual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423
7. Edwards R.J., et al. Development of a comprehensive panel of antibodies against the major xenobiotic metabolizing forms of cytochrome P450 in humans. Biochem. Pharmacol. 56:1998;377-387
8. Rodrigues A.D., Rushmore T.H. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr. Drug Metab. 3:2002;289-309
9. Lewis D.F.V. Human cytochromes P450 associated with the Phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem. 10:2003;1955-1972
10. Smith D.A. Chemistry and enzymology: their use in the prediction of human drug metabolism. Eur. J. Pharm. Sci. 2:1994;69-71
11. Smith D.A., van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 3:1999;373-378
12. Smith D.A., et al. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: active site characteristics. Drug Discov. Today. 2:1997;406-414
13. Smith D.A., et al. Properties of cytochrome P450 isoenzymes and the substrates. Part 2: properties of cytochrome P450 substrates. Drug Discov. Today. 2:1997;479-486
14. Lewis D.F.V., Dickins M. Substrate SARs in human P450s. Drug Discov. Today. 7:2002;918-925
15. Lewis D.F.V., Dickins M. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab. Rev. 35:2003;1-18
16. Hansch C., Zhang L. Quantitative structure-activity relationships of cytochrome P450. Drug Metab. Rev. 25:1993;1-48
17. m. Drug Metab. Rev. 28:1996;513-526
18. Sarver J.G., et al. Estimating xenobiotic half-lives in humans from rat data: influence of log P. Environ. Health Perspect. 105:1997;1204-1209
19. bind) for human P450 substrates. Curr. Drug Metab. 4:2003;331-340
20. Hansch C. A quantitative approach to biochemical structure-activity relationships. Acc. Chem. Res. 2:1969;232-239
21. Modi S. Computational approaches to the understanding of ADMET properties and problems. Drug Discov. Today. 8:2003;621-623
22. Leo A., et al. Partition coefficients and their uses. Chem. Rev. 71:1971;525-616
23. van de Waterbeemd H., et al. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44:2001;1313-1333
24. Kerns E.H., Di L. Pharmaceutical profiling in drug discovery. Drug Discov. Today. 8:2003;316-323
25. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today. 2:1997;436-444
26. Livingstone D.J. The characterization of chemical structures using molecular properties: a survey. J. Chem. Inf. Comput. Sci. 40:2000;195-209
27. van de Waterbeemd H., Testa B. The parametrization of lipophilicity and other structural properties in drug design. Adv. Drug Res. 16:1987;85-225
28. Kubinyi H. QSAR and 3D QSAR in drug design. Part 2: applications and problems. Drug Discov. Today. 2:1997;538-546
29. Clark D.E. Prediction of intestinal absorption and blood-brain barrier penetration by computational methods. Comb. Chem. High Throughput Screen. 4:2001;477-496
30. Cronin M.T.D., et al. Parametrization of electrophilicity for the prediction of the toxicity of aromatic compounds. Chem. Res. Toxicol. 14:2001;1498-1505
31. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug Deliv. Rev. 23:1997;3-25
32. Al-Gailany K.A.S., et al. The role of substrate lipophilicity in determining type 1 microsomal P450 binding characteristics. Biochem. Pharmacol. 27:1978;783-788
33. Ishigami M., et al. A comparison of the effectgs of 3-hydroxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab. Dispos. 29:2001;282-288
34. Austin R.P., et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30:2002;1497-1503
35. Riley R.J., et al. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm. Res. 18:2001;652-655
36. Ramos-Nino M.E., et al. Quantitative structure-activity relationship for the effect of benzoic acids, cinnamic acids and benzaldehydes on Listeria monocytogenes. J. Appl. Bacteriol. 80:1996;303-310
37. Ferrari S., et al. The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro. Life Sci. 48:1991;2259-2265
38. 2 and their partitioning into liposomal membranes. Biochem. J. 284:1992;483-490
39. Vermeir M., et al. Modelling of interaction of basic lipophilic ligands with cytochrome P450 reconstituted in liposomes. Determination of membrane partition coefficients of S(-)-nicotine and N, N-diethylaniline from spectral binding studies and fluorescence quenching. Biochim. Biophys. Acta. 1107:1992;93-104
40. Ekins S., Wrighton S.A. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:1999;719-754
41. Hansch C., Leo A.J. Substituent Constants for Correlation Analysis in Chemistry and Biology. 1979;Wiley, New York
42. Hansch C., et al. Exploring QSAR 2. Hydrophobic, Electronic and Steric Constants. 1995;American Chemical Society, Washington
43. Abraham M.H., et al. Application of hydrogen bonding calculations in property based drug design. Drug Discov. Today. 7:2002;1056-1063
44. Lewis, D.F.V. Hydrogen bonding in human P450-substrate interactions: a major contribution to binding affinity. Scientific World J. (in press)
45. Lewis D.F.V., Broughton H.B. Molecular binding interactions: their estimation and rationalization of QSARs in terms of theoretically derived parameters. Scientific World J. 2:2002;1776-1802
46. Winn P.J., et al. Comparison of the dynamics of substrate access in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5361-5366
47. Ekins S., et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29:2001;936-944
48. de Groot M.J., Ekins S. Pharmacophore modeling of cytochromes P450. Adv. Drug Deliv. Rev. 54:2002;367-383
49. Clark D.E., Pickett S.D. Computational methods for the prediction of 'drug-likeness'. Drug Discov. Today. 5:2000;49-57
50. Vaes W.H.J., et al. Understanding and estimating membrane/water partition coefficients: approaches to derive quantitative structure property relationships. Chem. Res. Toxicol. 11:1998;847-854
51. Meylan W.M., Howard P.H. Atom/fragment contribution method for estimating octanol-water partition coefficients. J. Pharm. Sci. 84:1995;83-92
52. Moriguchi I., et al. Simple method of calculating octanol/water partition coefficient. Chem. Pharm. Bull. (Tokyo). 40:1992;127-130
53. Moriguchi I., et al. Comparison of reliability of log P values for drugs calculated by several methods. Chem. Pharm. Bull. (Tokyo). 42:1994;976-978
54. oct: a tool for lipophilicity determination in drug discovery. J. Med. Chem. 43:2000;2922-2928
55. Pliska V.,, et al. Lipophilicity in Drug Action and Toxicology. 1996;VCH, Weinheim
56. Sangster J. Octanol-water partition coefficients of simple organic compounds. J. Phys. Chem. Ref. Data. 18:1989;1111-1229
57. Dias N.C., et al. Evaluation of a reversed-phase column (Supercosil LC-ABZ) under isocratic and gradient elution conditions for estimating octanol-water partition coefficients. Analyst. 128:2003;427-433
58. a values of medicinal compounds in pharmacy practice. Drug Intell. Clin. Pharm. 12:1978;546-554
59. Dean J.A. Lange's Handbook of Chemistry. 14th edn :1992;McGraw-Hill
60. Lewis D.F.V., et al. Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions. Drug Metabol. Drug Interact. 19:2003;115-135
61. Levitt M., Perutz M.F. Aromatic rings act as hydrogen bond donors. J. Mol. Biol. 201:1988;751-754